Compare IPCA Labs with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs STRIDES PHARMA SCIENCE - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS STRIDES PHARMA SCIENCE IPCA LABS/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 22.4 14.4 155.7% View Chart
P/BV x 4.4 0.9 510.9% View Chart
Dividend Yield % 0.1 0.6 18.9%  

Financials

 IPCA LABS   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    IPCA LABS
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
IPCA LABS/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs6951,147 60.6%   
Low Rs400642 62.3%   
Sales per share (Unadj.) Rs260.2317.2 82.0%  
Earnings per share (Unadj.) Rs19.07.8 241.8%  
Cash flow per share (Unadj.) Rs33.125.1 131.9%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.2 81.7%  
Book value per share (Unadj.) Rs213.0274.3 77.7%  
Shares outstanding (eoy) m126.2089.50 141.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.12.8 74.7%   
Avg P/E ratio x28.9114.0 25.3%  
P/CF ratio (eoy) x16.635.7 46.4%  
Price / Book Value ratio x2.63.3 78.8%  
Dividend payout %5.325.5 20.7%   
Avg Mkt Cap Rs m69,12080,058 86.3%   
No. of employees `00013.32.5 528.7%   
Total wages/salary Rs m7,3594,341 169.5%   
Avg. sales/employee Rs Th2,477.411,325.8 21.9%   
Avg. wages/employee Rs Th555.21,731.4 32.1%   
Avg. net profit/employee Rs Th180.6280.1 64.5%   
INCOME DATA
Net Sales Rs m32,83628,394 115.6%  
Other income Rs m418941 44.4%   
Total revenues Rs m33,25429,334 113.4%   
Gross profit Rs m4,5053,965 113.6%  
Depreciation Rs m1,7771,540 115.4%   
Interest Rs m2401,962 12.2%   
Profit before tax Rs m2,9051,403 207.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m51197 525.3%   
Profit after tax Rs m2,394702 341.0%  
Gross profit margin %13.714.0 98.2%  
Effective tax rate %17.66.9 253.7%   
Net profit margin %7.32.5 294.9%  
BALANCE SHEET DATA
Current assets Rs m19,45524,836 78.3%   
Current liabilities Rs m10,07618,993 53.0%   
Net working cap to sales %28.620.6 138.8%  
Current ratio x1.91.3 147.7%  
Inventory Days Days9871 137.9%  
Debtors Days Days67113 59.0%  
Net fixed assets Rs m20,26034,289 59.1%   
Share capital Rs m252895 28.2%   
"Free" reserves Rs m26,63323,651 112.6%   
Net worth Rs m26,88624,546 109.5%   
Long term debt Rs m2,34015,513 15.1%   
Total assets Rs m41,17365,437 62.9%  
Interest coverage x13.11.7 763.6%   
Debt to equity ratio x0.10.6 13.8%  
Sales to assets ratio x0.80.4 183.8%   
Return on assets %6.44.1 157.1%  
Return on equity %8.92.9 311.3%  
Return on capital %10.86.9 156.1%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64215,697 99.6%   
Fx outflow Rs m4,884735 664.1%   
Net fx Rs m10,75914,962 71.9%   
CASH FLOW
From Operations Rs m3,4111,871 182.4%  
From Investments Rs m-1,3545,826 -23.2%  
From Financial Activity Rs m-1,304-10,157 12.8%  
Net Cashflow Rs m753-2,615 -28.8%  

Share Holding

Indian Promoters % 45.9 27.7 165.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 37.8 30.2%  
FIIs % 25.3 8.6 294.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 25.9 67.2%  
Shareholders   36,892 56,241 65.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Oct 22, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - PFIZER COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS